• An empty laboratory
    Image attribution tooltip
    Alvarez via Getty Images

    Celularity warns of layoffs for ‘substantial portion’ of its staff

    After a strategic review, the Celgene spinout said it won’t advance two experimental cancer therapies that use “natural killer” cells.

    By Jan. 27, 2023
  • Veteran biotech leader George Scangos to step down as Vir CEO

    The former Biogen head is retiring after taking Vir from a small startup to a publicly traded developer of infectious disease drugs. Bayer executive Marianne De Backer will succeed him.

    By Jan. 25, 2023
  • Single strand ribonucleic acid, RNA research Explore the Trendline
    Image attribution tooltip
    luismmolina via Getty Images

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • A photo of the three founders of Dimension
    Image attribution tooltip
    Permission granted by Dimension
    Emerging biotech

    Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’

    The veteran investors see the marriage of tech and life sciences as the “largest opportunity in venture today,” said co-founder and former Lux Capital general partner Adam Goulburn.

    By Jan. 25, 2023
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Q&A // Emerging biotech

    Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

    The year ahead could be turbulent for biotech as investors look for what the Roivant CEO described to BioPharma Dive as “safe harbors in a storm.”

    By Jan. 24, 2023
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive

    FDA to seek outside advice on Biogen’s ALS drug

    The agency plans to convene a panel of experts on March 22 to discuss the approval application for tofersen, a closely watched medicine Biogen submitted to the FDA despite its failure in a key clinical trial.

    By Jan. 24, 2023
  • A photograph of an empty laboratory.
    Image attribution tooltip
    gorodenkoff via Getty Images

    Finch to lay off 95% of staff, scrap microbiome drug study

    The company blamed a range of factors in its decision, including limited funding options, slow trial enrollment and “broader sector trends.”

    By Jan. 24, 2023
  • Little girl being treated in a clinic
    Image attribution tooltip


    Sponsored by Cardinal Health

    How CAR-T therapies are revolutionizing cancer treatments

    One of the most significant advancements made in treating disease in recent years is the development and commercialization of CAR-T therapy, which weaponizes a patient’s own white blood cells to attack certain types of blood cancer cells.

    Jan. 23, 2023
  • A screenshot of BioPharma Dive editor Chris Newman speaking with three biotech executives during an online webinar
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive

    3 biotech executives on the year ahead: deals, drug pricing and the down market

    “What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.

    By Jan. 19, 2023
  • A photograph of Editas Medicine CEO Gilmore O'Neill
    Image attribution tooltip
    Courtesy of Editas Medicine

    Editas, in next restructuring step, to sell cell therapy work to Shoreline

    Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology. 

    By Jan. 19, 2023
  • A photo of former U.S. Commerce Secretary Wilbur Ross
    Image attribution tooltip
    Chip Somodevilla via Getty Images

    Neurology startup to merge with Wilbur Ross-backed SPAC

    The deal, which comes during a prolonged downturn in SPAC activity among biotechs, will help fund development of an Alzheimer’s drug that’s in late-stage testing in China. 

    By Kristin Jensen • Jan. 18, 2023
  • The Wall Street Bull srrounded by passing people
    Image attribution tooltip
    Spencer Platt/Getty via Getty Images
    Emerging biotech

    With reverse merger, Elicio becomes latest biotech to bypass an IPO

    Elicio’s combination with Angion Biomedica comes months after it abandoned a new stock offering, and is the latest example of how the IPO slowdown has shifted startups’ plans.

    By Jan. 17, 2023
  • A photo of Alfred Sandrock, former chief medical officer and head of R&D at Biogen
    Image attribution tooltip
    Courtesy of Business Wire

    Al Sandrock on his short retirement and taking on a biotech turnaround project

    In a conversation at the J.P. Morgan Healthcare conference, the longtime Biogen executive discussed his hesitance to jump back into an executive role and why an opportunity to run Voyager Therapeutics drew him in.

    By Jan. 17, 2023
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi

    Sanofi tops off venture arm, bringing fund to $750M

    The pharma is rolling out a multi-year capital commitment to its biotech investment group, which this week backed biotech NextPoint Therapeutics.

    By Kristin Jensen • Jan. 12, 2023
  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive

    JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas

    Venture investors cautioned of a coming funding crunch for young biotechs, while the FDA commissioner shared advice for drugmakers.

    By , , Jan. 10, 2023
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen

    New Biogen CEO seeks to ‘redefine’ company after challenging year

    Christopher Viehbacher, who took over as head of the biotech late last year, aims to better balance Biogen’s high-risk, high-reward drug pipeline, but said he’d avoid making “radical left turns.”

    By Jan. 10, 2023
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Emerging biotech

    5 questions facing emerging biotech in 2023

    Investors expect another lackluster year in IPOs, while company restructurings look set to continue as biotech executives try to conserve cash.

    By Jan. 10, 2023
  • An image of liver cirrhosis
    Image attribution tooltip
    klickit24 via Getty Images

    Arrowhead reports positive data from liver drug, but company’s shares slide

    The biotech and partner Takeda also announced a Phase 3 study of the RNA medicine that is longer than anticipated, pushing out analysts’ timelines.

    By Jan. 9, 2023
  • A photograph of Editas Medicine CEO Gilmore O'Neill
    Image attribution tooltip
    Courtesy of Editas Medicine

    Editas to cut jobs, narrow research focus in restructuring

    The CRISPR-focused biotech will lay off 20% of its workforce, stop development of two eye disease treatments and end some early-stage cell therapy research. 

    By Updated Jan. 9, 2023
  • Gene therapy of the DNA cell, low-poly design of a human hand with a syringe and a spiral-shaped chromosome. Blue background.
    Image attribution tooltip


    Sponsored by Allucent

    Focusing on smaller biotechs to have a big impact on society

    Marcus Delatte discusses how and why he focuses his expertise on counseling smaller companies and mentoring the next generation of technical experts.

    Jan. 9, 2023
  • Image attribution tooltip
    Viktor Chebanenko via Getty Images

    Ensoma buys a startup to advance ‘in vivo’ cell therapy work

    The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio.

    By Jan. 6, 2023
  • Illustration of a macrophage devouring a cancer cell.
    Image attribution tooltip
    Design Cells via Getty Images

    Fate, two other cell therapy biotechs lay off staff, restructure research

    The cuts at Fate, Century and TCR2 Therapeutics signal a longer road in the companies’ plans to develop next-generation cell therapies for cancer.

    By Jan. 6, 2023
  • A photo of Bluebird bio signage in a corporate lobby
    Image attribution tooltip
    Permission granted by Bluebird bio

    Bluebird bolsters balance sheet with sale of second regulatory fast pass

    The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.

    By Jan. 6, 2023
  • Illustration of lung cancer
    Image attribution tooltip
    SciePro via Getty Images

    Novocure shares soar on positive lung cancer data

    A regimen involving the Swiss biotech’s electrical field-based treatment extended lives in a late-stage trial. But data comparing the medical device to standard chemotherapy is less persuasive.

    By Jan. 5, 2023
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen

    Biogen splits R&D executive role, promoting interim head Singhal

    Singhal, who took over R&D leadership on an interim basis from Al Sandrock, will lead Biogen’s development work while the company searches for a new research chief.

    By Kristin Jensen • Jan. 5, 2023
  • New York Stock Exchange.
    Image attribution tooltip
    "ASE" by LeoTar is licensed under CC BY-SA 3.0

    Sesen, Carisma merger plans draw shareholder opposition

    Investors holding an 8% stake in Sesen say they’re unhappy with the reverse merger between the struggling biotech and Carisma Therapeutics.

    By Jan. 4, 2023